Literature DB >> 12898179

Inhibitory effect of cyclo-oxygenase-2 inhibitor on the production of matrix metalloproteinases in rheumatoid fibroblast-like synoviocytes.

H S Cha1, K S Ahn, C H Jeon, J Kim, E M Koh.   

Abstract

Cyclo-oxygenase (COX)-2 has been associated with inflammation in rheumatoid arthritis (RA), but its role in joint destruction remains unclear. In this study, we investigated the effect on cultured rheumatoid fibroblast-like synoviocytes (FLS) of the selective COX-2 inhibitor celecoxib on the expression of matrix metalloproteinases (MMPs), which play an important role in tissue degradation and angiogenesis in rheumatoid synovium. Treatment with nontoxic doses of celecoxib resulted in dose-dependent inhibition of MMP-1, -2, and -3 secretion from FLS when measured by enzyme-linked immunosorbent assay. Celecoxib suppressed proinflammatory cytokines (tumor necrosis factor-alpha and interleukin-1beta) induced augmentation of the gelatinolytic activity on zymography. These results suggest that COX-2 inhibitors might influence matrix degradation or angiogenesis in RA by downregulating the expression of various MMPs in rheumatoid FLS.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12898179     DOI： 10.1007/s00296-003-0359-3

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN： 0172-8172            Impact factor:   2.631


  31 in total

Review 1.  Pathogenesis of rheumatoid arthritis: the role of synoviocytes.

Authors:  Y Yamanishi; G S Firestein
Journal:  Rheum Dis Clin North Am       Date:  2001-05       Impact factor: 2.670

2.  In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis.

Authors:  H Sano; T Hla; J A Maier; L J Crofford; J P Case; T Maciag; R L Wilder
Journal:  J Clin Invest       Date:  1992-01       Impact factor: 14.808

Review 3.  Cyclooxygenases 1 and 2.

Authors:  J R Vane; Y S Bakhle; R M Botting
Journal:  Annu Rev Pharmacol Toxicol       Date:  1998       Impact factor: 13.820

Review 4.  Cyclooxygenase in biology and disease.

Authors:  R N Dubois; S B Abramson; L Crofford; R A Gupta; L S Simon; L B Van De Putte; P E Lipsky
Journal:  FASEB J       Date:  1998-09       Impact factor: 5.191

5.  Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas.

Authors:  T Hida; Y Yatabe; H Achiwa; H Muramatsu; K Kozaki; S Nakamura; M Ogawa; T Mitsudomi; T Sugiura; T Takahashi
Journal:  Cancer Res       Date:  1998-09-01       Impact factor: 12.701

6.  Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases.

Authors:  I Siegle; T Klein; J T Backman; J G Saal; R M Nüsing; P Fritz
Journal:  Arthritis Rheum       Date:  1998-01

7.  Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.

Authors:  C C Chan; S Boyce; C Brideau; S Charleson; W Cromlish; D Ethier; J Evans; A W Ford-Hutchinson; M J Forrest; J Y Gauthier; R Gordon; M Gresser; J Guay; S Kargman; B Kennedy; Y Leblanc; S Leger; J Mancini; G P O'Neill; M Ouellet; D Patrick; M D Percival; H Perrier; P Prasit; I Rodger
Journal:  J Pharmacol Exp Ther       Date:  1999-08       Impact factor: 4.030

8.  Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases.

Authors:  F A Attiga; P M Fernandez; A T Weeraratna; M J Manyak; S R Patierno
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

9.  Effect of etodolac on type-II collagen-induced arthritis in mice.

Authors:  K Inoue; A Motonaga; H Suzuka; H Yoshifusa; H Fujisawa; T Nishimura; Y Inoue; F Ueda; Y Shibata; K Kimura
Journal:  Agents Actions       Date:  1993-07

10.  Human cyclooxygenase-2 cDNA.

Authors:  T Hla; K Neilson
Journal:  Proc Natl Acad Sci U S A       Date:  1992-08-15       Impact factor: 11.205
View more
  5 in total

1.  Molecular mechanism of the inhibition effect of Celecoxib on corneal collagen degradation in three dimensions.

Authors:  Wen-Song Zhang; Ji-Long Hao; Shuang Wang; Miao-Miao Bi; Hong Zhang; Hong-Yan Zhou
Journal:  Int J Ophthalmol       Date:  2012-08-18       Impact factor: 1.779

2.  Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29).

Authors:  M Gallicchio; A C Rosa; C Dianzani; L Brucato; E Benetti; M Collino; R Fantozzi
Journal:  Br J Pharmacol       Date:  2007-12-17       Impact factor: 8.739

3.  Celecoxib inhibits production of MMP and NO via down-regulation of NF-kappaB and JNK in a PGE2 independent manner in human articular chondrocytes.

Authors:  R Tsutsumi; H Ito; T Hiramitsu; K Nishitani; M Akiyoshi; T Kitaori; T Yasuda; T Nakamura
Journal:  Rheumatol Int       Date:  2007-12-14       Impact factor: 2.631

Review 4.  Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis.

Authors:  Manon C Zweers; Tineke N de Boer; Joël van Roon; Johannes W J Bijlsma; Floris P J G Lafeber; Simon C Mastbergen
Journal:  Arthritis Res Ther       Date:  2011-09-21       Impact factor: 5.156

5.  Local IL-13 gene transfer prior to immune-complex arthritis inhibits chondrocyte death and matrix-metalloproteinase-mediated cartilage matrix degradation despite enhanced joint inflammation.

Authors:  Karin C A M Nabbe; Peter L E M van Lent; Astrid E M Holthuysen; Annet W Sloëtjes; Alisa E Koch; Timothy R D J Radstake; Wim B van den Berg
Journal:  Arthritis Res Ther       Date:  2005-01-26       Impact factor: 5.156
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.